Resultado da pesquisa (3)
Termo utilizado na pesquisa inactivated vaccine
#1 - Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine, p.545-551
Abstract in English:
Abstract.- Silva A.D., Esteves P.A., Dezen D., Oliveira A.P., Spilki F.R., Campos F.S., Franco A.C. & Roehe P.M. 2009. Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine. Pesquisa Veterinária Brasileira 29(7):545-551. Instituto de Pesquisas Veterinárias Desidério Finamor, Fepagro Saúde Animal, Estrada do Conde 6000, Cx. Postal 47, Eldorado do Sul, RS 92990-000, Brazil. E-mail: proehe@gmail.com
Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE-). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 107.0 fifty per cent cell culture infectious doses (CCID50) of 265gE-. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE- recombinant was shown to be suitable for use as a vaccine.
Abstract in Portuguese:
Abstract.- Silva A.D., Esteves P.A., Dezen D., Oliveira A.P., Spilki F.R., Campos F.S., Franco A.C. & Roehe P.M. 2009. Efficacy of a gE-deleted, bovine herpesvirus 1 (BoHV-1) inactivated vaccine. Pesquisa Veterinária Brasileira 29(7):545-551. Instituto de Pesquisas Veterinárias Desidério Finamor, Fepagro Saúde Animal, Estrada do Conde 6000, Cx. Postal 47, Eldorado do Sul, RS 92990-000, Brazil. E-mail: proehe@gmail.com
Bovine herpesvirus type 1 (BoHV-1) is recognized as a major cause of economic losses in cattle. Vaccination has been widely applied to minimize losses induced by BoHV-1 infections. We have previously reported the development of a differential BoHV-1 vaccine, based on a recombinant glycoprotein E (gE)-deleted virus (265gE-). In present paper the efficacy of such recombinant was evaluated as an inactivated vaccine. Five BoHV-1 seronegative calves were vaccinated intramuscularly on day 0 and boostered 30 days later with an inactivated, oil adjuvanted vaccine containing an antigenic mass equivalent to 107.0 fifty per cent cell culture infectious doses (CCID50) of 265gE-. Three calves were kept as non vaccinated controls. On day 60 post vaccination both vaccinated and controls were challenged with the virulent parental strain. No clinical signs or adverse effects were seen after or during vaccination. After challenge, 2/5 vaccinated calves showed mild clinical signs of infection, whereas all non vaccinated controls displayed intense rhinotracheitis and shed virus for longer and to higher titres than vaccinated calves. Serological responses were detected in all vaccinated animals after the second dose of vaccine, but not on control calves. Following corticosteroid administration in attempting to induce reactivation of the latent infection, no clinical signs were observed in vaccinated calves, whereas non vaccinated controls showed clinical signs of respiratory disease. In view of its immunogenicity and protective effect upon challenge with a virulent BoHV-1, the oil adjuvanted preparation with the inactivated 265gE- recombinant was shown to be suitable for use as a vaccine.
#2 - Evaluation of an inactivated vaccine against caseous lymphadenitis of goats kept under extensive management
Abstract in English:
The experiment was carried out during a 2-year period (Oct. 1981 to Oct. 1983), using 163 goats of both sexes with 6 to 12 months of age, The objective was to evaluate the immunogenicity of a vaccine against caseous lymphadenitis, in northeastem Bahia. The vaccine was developed, utilizing the local strain 1002 Curaçá of Corynebacterium pseudotuberculosis isolated from na abscess of a goat. For the preparation, tryptose broth, enriched with yeast extract and lactalbumin, was used. Inactivation was effected with 0.5% formaldehyde, and aluminum gel phosphate was used as an adjuvant. The cell volume varied from 0.65 to 0.7%. The experiment consisted of the following treatments: A1 - animals vaccinated every 6 months; A2-animals vaccinated once a year; and A3 - animals not vaccinated. The goats were vaccinated by subcutaneous inoculation of 3 ml vaccine into each axillar region, and post-mortem examination was made at the end of the experiment. The results showed that 72.1% of the control animals (A3) had moderate to severe lesions in different lymphnodes, and in some cases in the internai organs. Of the vaccinated animals, only 25.9% and 18.9%, at 6 and 12 months interval respectively, showed discrete lesions which were restricted to no more than three lymphnodes per animal. There was a signif cant difference (P<0,05) between the vaccinated and the non-vaccinated animals, but no difference between treatment A1 and A2. It can be estimated that the vaccination gave a protection of 77% against the disease.
Abstract in Portuguese:
Foram utilizados 163 caprinos de ambos os sexos, de 6 a 12 meses de idade, com o objetivo de avaliar a imunogenicidade de uma vacina contra a linfadenite caseosa, no Nordeste do Estado da Bahia. A vacina foi elaborada com a cepa 1002 Curaçá de C. pseudotuberculosis, isolada de abscesso de caprino, cultivada em caldo tryptose, enriquecida com extrato de levedura mais lactalbumina e inativada com formaldeído a 0,5% durante 7 dias, utilizando-se como adjuvante o gel fosfato de alumínio. O volume celular variou de 0,65 a 0,70%. O experimento constituiu-se dos seguintes tratamentos: A1 - animais vacinados semestralmente; A2 - vacinados anualmente; A3 - animais não vacinados. Os animais vacinados foram inoculados via subcutânea com 3 ml da vacina em cada região axilar e, ao final do experimento, foram necropsiados. Os resultados mostraram que 72,1 % dos caprinos do grupo testemunha A3 se infectaram naturalmente e apresentaram lesão moderada a severa em vários linfonodos e, em alguns casos, nos órgãos internos. Dos vaciandos, apenas 25,9 e 18,9%, respectivamente, para os revacinados com 6 e 12 meses de intervalo, apresentaram lesões discretas que se restringiram a não mais de três linfonodos por animal. Houve diferença significativa (P<0,05) entre os animais vacinados e não vacinados mas não houve diferença entre os tratamentos A1 e A2. Pode-se estimar que a vacina proporcionou 77% de proteção contra a doença.
#3 - Immunoprophylaxis of swine pleuropneumonia with an inactivated vaccine against Haemo-philus pleuropneumoniae
Abstract in English:
The effectiveness of a bacterin in the prevention of pleuropneumonia of swine was tested. The bacterin was prepared from a strain of H. pleuropneumoniae, serotype 5, and adsorved to aluminum hydroxide. Six sows were vaccinated at 60 and 100 days of gestation (VS) and seven were not vaccinated (NVS). Piglets born to VS were divided into three treatment groups: unvaccinated; vaccinated at 40 days of age; and vaccinated at 25 and 40 days of age. Those born to the NVS were divided into two groups: unvaccinated and vaccinated at 25 and 40 days of age. On third of the piglets from each treatment groups was challenged with a strain of H. pleuropneumoniae, serotype 5, at 70 days of age. In piglets born to VS, respiratory symptoms were observed less frequently, H. pleuropneumoniae was found less often in the nasal cavity after challenge, a lower mortality rate was noted, and less severe lesions characteristic of pleuropneumonia were seen than in piglets born to NVS. Piglet vaccination schedules did not interfere with the above mentioned parameters.
Abstract in Portuguese:
Testou-se a eficiência de uma bacterina preparada com H. pleuropneumoniae, sorotipo 5, e adsorvida em hidróxido de alumínio, na prevenção de pleuropneumonia suína. Vacinou-se seis matrizes (MV) aos 60 e 100 dias de gestação, e sete não foram vacinadas (MNV). Os leitões originados das MV foram divididos em três tratamentos: não vacinados, vacinados aos 40 dias e aos 25 e 40 dias de idade. Os originados das MNV foram divididos em dois grupos: vacinados aos 25 e 40 dias e não vacinados. Um terço dos leitões de cada tratamento foi inoculado com H. pleuropneumoniae, sorotipo 5, aos 70 dias de idade. Leitões originados de MV apresentaram menor ocorrência de sintomas respiratórios, menor presença de H. pleuropneumoniae na cavidade nasal apos a agressão, menor índice de mortalidade e menor ocorrência de severidade de lesões compatíveis com a pleuropneumonia suína do que aqueles originados de MNV. Os esquemas de vacinação aplicados aos leitões no interferiram nos parâmetros acima mencionados.
